Update and new approaches in the treatment of Castleman disease
Kah-Lok Chan, Stephen Lade, H Miles Prince, Simon J Harrison
JOURNAL OF BLOOD MEDICINE | DOVE MEDICAL PRESS LTD | Published : 2016
First described 60 years ago, Castleman disease comprises a rare and heterogeneous cluster of disorders, characterized by lymphadenopathy with unique histological features and associated with cytokine-driven constitutional symptoms and biochemical disturbances. Although unicentric Castleman disease is curable with complete surgical excision, its multicentric counterpart is a considerable therapeutic challenge. The recent development of biological agents, particularly monoclonal antibodies to interleukin-6 and its receptor, allow for more targeted disease-specific intervention that promises improved response rates and more durable disease control; however, further work is required to fill kno..View full abstract
SJH has received funding from Janssen-Cilag for the conduct of clinical trials and participation in advisory boards in relation to Castleman disease. The authors report no other conflicts of interest in this work.